Cargando…

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Datsen George, Chiang, Vicki, Fyne, Elizabeth, Balakrishnan, Mini, Barnes, Tiffany, Graupe, Michael, Hesselgesser, Joseph, Irrinki, Alivelu, Murry, Jeffrey P., Stepan, George, Stray, Kirsten M., Tsai, Angela, Yu, Helen, Spindler, Jonathan, Kearney, Mary, Spina, Celsa A., McMahon, Deborah, Lalezari, Jacob, Sloan, Derek, Mellors, John, Geleziunas, Romas, Cihlar, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983056/
https://www.ncbi.nlm.nih.gov/pubmed/24722454
http://dx.doi.org/10.1371/journal.ppat.1004071
_version_ 1782311250965823488
author Wei, Datsen George
Chiang, Vicki
Fyne, Elizabeth
Balakrishnan, Mini
Barnes, Tiffany
Graupe, Michael
Hesselgesser, Joseph
Irrinki, Alivelu
Murry, Jeffrey P.
Stepan, George
Stray, Kirsten M.
Tsai, Angela
Yu, Helen
Spindler, Jonathan
Kearney, Mary
Spina, Celsa A.
McMahon, Deborah
Lalezari, Jacob
Sloan, Derek
Mellors, John
Geleziunas, Romas
Cihlar, Tomas
author_facet Wei, Datsen George
Chiang, Vicki
Fyne, Elizabeth
Balakrishnan, Mini
Barnes, Tiffany
Graupe, Michael
Hesselgesser, Joseph
Irrinki, Alivelu
Murry, Jeffrey P.
Stepan, George
Stray, Kirsten M.
Tsai, Angela
Yu, Helen
Spindler, Jonathan
Kearney, Mary
Spina, Celsa A.
McMahon, Deborah
Lalezari, Jacob
Sloan, Derek
Mellors, John
Geleziunas, Romas
Cihlar, Tomas
author_sort Wei, Datsen George
collection PubMed
description Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model of HIV latency, RMD was the most potent inducer of HIV (EC(50) = 4.5 nM) compared with vorinostat (VOR; EC(50) = 3,950 nM) and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC(50) = 10 nM). The HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA levels, whereas a 24-hour treatment with 1 µM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison, the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating that the drug may reactivate latent HIV in patients on suppressive cART.
format Online
Article
Text
id pubmed-3983056
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39830562014-04-15 Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing Wei, Datsen George Chiang, Vicki Fyne, Elizabeth Balakrishnan, Mini Barnes, Tiffany Graupe, Michael Hesselgesser, Joseph Irrinki, Alivelu Murry, Jeffrey P. Stepan, George Stray, Kirsten M. Tsai, Angela Yu, Helen Spindler, Jonathan Kearney, Mary Spina, Celsa A. McMahon, Deborah Lalezari, Jacob Sloan, Derek Mellors, John Geleziunas, Romas Cihlar, Tomas PLoS Pathog Research Article Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model of HIV latency, RMD was the most potent inducer of HIV (EC(50) = 4.5 nM) compared with vorinostat (VOR; EC(50) = 3,950 nM) and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC(50) = 10 nM). The HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA levels, whereas a 24-hour treatment with 1 µM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison, the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating that the drug may reactivate latent HIV in patients on suppressive cART. Public Library of Science 2014-04-10 /pmc/articles/PMC3983056/ /pubmed/24722454 http://dx.doi.org/10.1371/journal.ppat.1004071 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Wei, Datsen George
Chiang, Vicki
Fyne, Elizabeth
Balakrishnan, Mini
Barnes, Tiffany
Graupe, Michael
Hesselgesser, Joseph
Irrinki, Alivelu
Murry, Jeffrey P.
Stepan, George
Stray, Kirsten M.
Tsai, Angela
Yu, Helen
Spindler, Jonathan
Kearney, Mary
Spina, Celsa A.
McMahon, Deborah
Lalezari, Jacob
Sloan, Derek
Mellors, John
Geleziunas, Romas
Cihlar, Tomas
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
title Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
title_full Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
title_fullStr Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
title_full_unstemmed Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
title_short Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
title_sort histone deacetylase inhibitor romidepsin induces hiv expression in cd4 t cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983056/
https://www.ncbi.nlm.nih.gov/pubmed/24722454
http://dx.doi.org/10.1371/journal.ppat.1004071
work_keys_str_mv AT weidatsengeorge histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT chiangvicki histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT fyneelizabeth histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT balakrishnanmini histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT barnestiffany histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT graupemichael histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT hesselgesserjoseph histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT irrinkialivelu histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT murryjeffreyp histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT stepangeorge histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT straykirstenm histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT tsaiangela histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT yuhelen histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT spindlerjonathan histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT kearneymary histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT spinacelsaa histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT mcmahondeborah histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT lalezarijacob histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT sloanderek histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT mellorsjohn histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT geleziunasromas histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing
AT cihlartomas histonedeacetylaseinhibitorromidepsininduceshivexpressionincd4tcellsfrompatientsonsuppressiveantiretroviraltherapyatconcentrationsachievedbyclinicaldosing